Publications in collaboration with researchers from Hôpital d'instruction des armées Bégin (4)

2021

  1. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

    ESMO Open, Vol. 6, Núm. 5

  2. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

    European Urology, Vol. 80, Núm. 4, pp. 497-506

2020

  1. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525

2019

  1. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

    New England Journal of Medicine, Vol. 381, Núm. 26, pp. 2506-2518